<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6989424</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.00016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koblischke</surname><given-names>Maximilian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/535078/overview"/></contrib><contrib contrib-type="author"><name><surname>Spitzer</surname><given-names>Felicia S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/868311/overview"/></contrib><contrib contrib-type="author"><name><surname>Florian</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/844723/overview"/></contrib><contrib contrib-type="author"><name><surname>Aberle</surname><given-names>Stephan W.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/123825/overview"/></contrib><contrib contrib-type="author"><name><surname>Malafa</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/531615/overview"/></contrib><contrib contrib-type="author"><name><surname>Fae</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cassaniti</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/690144/overview"/></contrib><contrib contrib-type="author"><name><surname>Jungbauer</surname><given-names>Christof</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knapp</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Laferl</surname><given-names>Hermann</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Gottfried</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/39795/overview"/></contrib><contrib contrib-type="author"><name><surname>Baldanti</surname><given-names>Fausto</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stiasny</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heinz</surname><given-names>Franz X.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/17370/overview"/></contrib><contrib contrib-type="author"><name><surname>Aberle</surname><given-names>Judith H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/522332/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Center for Virology, Medical University of Vienna</institution>, <addr-line>Vienna</addr-line>, <country>Austria</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna</institution>, <addr-line>Vienna</addr-line>, <country>Austria</country></aff><aff id="aff3"><sup>3</sup><institution>Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo</institution>, <addr-line>Pavia</addr-line>, <country>Italy</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia</institution>, <addr-line>Pavia</addr-line>, <country>Italy</country></aff><aff id="aff5"><sup>5</sup><institution>Blood Service for Vienna, Lower Austria and Burgenland, Austrian Red Cross</institution>, <addr-line>Vienna</addr-line>, <country>Austria</country></aff><aff id="aff6"><sup>6</sup><institution>Data Science Section, Symptoma GmbH</institution>, <addr-line>Vienna</addr-line>, <country>Austria</country></aff><aff id="aff7"><sup>7</sup><institution>Sozialmedizinisches Zentrum S&#x000fc;d, Kaiser-Franz-Josef-Spital</institution>, <addr-line>Vienna</addr-line>, <country>Austria</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lucia Lopalco, San Raffaele Hospital (IRCCS), Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Daniela Weiskopf, La Jolla Institute for Immunology (LJI), United States; Anthony Jaworowski, RMIT University, Australia</p></fn><corresp id="c001">*Correspondence: Judith H. Aberle <email>judith.aberle@meduniwien.ac.at</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><elocation-id>16</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>07</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Koblischke, Spitzer, Florian, Aberle, Malafa, Fae, Cassaniti, Jungbauer, Knapp, Laferl, Fischer, Baldanti, Stiasny, Heinz and Aberle.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Koblischke, Spitzer, Florian, Aberle, Malafa, Fae, Cassaniti, Jungbauer, Knapp, Laferl, Fischer, Baldanti, Stiasny, Heinz and Aberle</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>West Nile (WN) virus infection of humans is frequently asymptomatic, but can also lead to WN fever or neuroinvasive disease. CD4 T cells and B cells are critical in the defense against WN virus, and neutralizing antibodies, which are directed against the viral glycoprotein E, are an accepted correlate of protection. For the efficient production of these antibodies, B cells interact directly with CD4 helper T cells that recognize peptides from E or the two other structural proteins (capsid-C and membrane-prM/M) of the virus. However, the specific protein sites yielding such helper epitopes remain unknown. Here, we explored the CD4 T cell response in humans after WN virus infection using a comprehensive library of overlapping peptides covering all three structural proteins. By measuring T cell responses in 29 individuals with either WN virus disease or asymptomatic infection, we showed that CD4 T cells focus on peptides in specific structural elements of C and at the exposed surface of the pre- and postfusion forms of the E protein. Our data indicate that these immunodominant epitopes are recognized in the context of multiple different HLA molecules. Furthermore, we observed that immunodominant antigen regions are structurally conserved and similarly targeted in other mosquito-borne flaviviruses, including dengue, yellow fever, and Zika viruses. Together, these findings indicate a strong impact of virion protein structure on epitope selection and antigenicity, which is an important issue to consider in future vaccine design.</p></abstract><kwd-group><kwd>West Nile virus</kwd><kwd>flavivirus</kwd><kwd>CD4 T cell</kwd><kwd>immunodominance</kwd><kwd>epitope</kwd><kwd>West Nile patients</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Austrian Science Fund<named-content content-type="fundref-id">10.13039/501100002428</named-content></funding-source><award-id rid="cn001">P29881-B30</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="0"/><ref-count count="77"/><page-count count="14"/><word-count count="9829"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>West Nile (WN) virus is a mosquito-borne flavivirus that has caused repeated epidemics in the Americas since its first appearance in 1999, with more than 48,000 documented human cases and ~2,300 deaths (<xref rid="B1" ref-type="bibr">1</xref>). In addition, several recent WN virus outbreaks have been reported in Europe, the largest in 2018, involving over 2,000 human cases in 15 countries (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>). Although most WN virus infections remain asymptomatic (<xref rid="B4" ref-type="bibr">4</xref>), about 20% of humans develop symptoms of WN fever, and about one in 150 develop acute neuroinvasive disease (<xref rid="B5" ref-type="bibr">5</xref>). Despite significant disease burden, there is no specific treatment or vaccine against WN virus licensed for human use. Protective immunity to WN virus has been mainly attributed to neutralizing antibodies, which are essential for the clearance of infection and long-term immunity against disease (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). CD4 T cells also play critical roles in the defense against WN virus, both by promoting protective antibody responses and by direct killing of infected cells (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Despite this central role, the factors influencing the development of effective WN virus-specific CD4 T cell responses, specifically the sites in virus proteins giving rise to dominant CD4 T cell epitopes, remain unknown.</p><p>Like flaviviruses in general, mature WN virus particles consist of a nucleocapsid, which is composed of the single-stranded RNA genome and multiple copies of the capsid (C) protein, as well as a lipid envelope with two membrane-associated proteins, the membrane (M) protein, and the envelope (E) protein (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The M protein is generated by proteolytic cleavage of a precursor (prM) that is a component of immature virions (<xref rid="B11" ref-type="bibr">11</xref>) (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The E protein contains three distinct domains (domains I&#x02013;III) and a so-called stem region, followed by two transmembrane domains. Upon entry into host cells, the acidic pH of the endosome triggers an irreversible conformational change in the E protein that leads to membrane fusion and converts the metastable pre-fusion dimer into a stable post-fusion trimer (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Due to its important cell entry functions, the E protein is the major target of neutralizing antibodies (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). CD4 T cells provide essential help for potent neutralizing antibody production by direct cell surface interactions with B cells and the recognition of antigenic peptides presented with major histocompatibility complex class II (MHC II) molecules. Peptides for such direct help can derive from the E protein, recognized by the B cells or the two other structural proteins (M and C) that are co-internalized as part of the virus particle.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>CD4 T Cell Responses to WN Virus. <bold>(A)</bold> Schematic representation of immature and mature flavivirus particles. The virion contains three structural proteins: C (capsid), prM (pre-membrane) in immature and M (membrane) in mature virus particles, and E (envelope). The E protein consists of three domains, DI (red), DII (yellow), DIII (blue), as well as the stem (purple) and transmembrane region (gray). <bold>(B)</bold> Individual CD4 T cell responses from WN virus-infected subjects and na&#x000ef;ve controls to WN virus peptide pools covering the entire sequences of structural proteins C, prM and E, as determined by IL-2 ELISPOT assays. Results are shown as spot forming cells (SFCs) per million CD8-depleted PBMCs. Medians are displayed as black lines. The dashed line represents the cut-off value for assay positivity. <bold>(C)</bold> Percentage of spots contributed by C, prM and E in WN virus-infected subjects.</p></caption><graphic xlink:href="fimmu-11-00016-g0001"/></fig><p>The mechanisms influencing peptide presentation are incompletely understood, but a number of factors have been shown to affect the selection of epitopes during different stages of antigen processing. These include protein sequence-related factors, such as protease cleavage sites and MHC binding affinity (<xref rid="B14" ref-type="bibr">14</xref>). Furthermore, growing evidence suggests that protein structural features can modulate the efficacy of epitope generation during antigen processing (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>). In addition, it has been suggested that conformational changes of viral envelope proteins at the early endosomal pH can influence the processing and presentation of certain peptides (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>An analysis of CD4 T cell epitopes in the context of the atomic structures of viral protein antigens may therefore provide important clues about how the dominance of certain epitopes is controlled by structural features. Recent studies examining immunodominant epitopes in the context of three-dimensional protein structures have led to the identification of critical CD4 T cell epitopes in other flaviviruses, including Zika, yellow fever (YF) and tick-borne encephalitis (TBE) viruses (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>). Crystallographic and cryo-EM studies have shown that the E proteins of flaviviruses are structurally very similar, whereas their sequences differ by up to 60% among distantly related flaviviruses (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>). This combination of structural conservation and sequence divergence provides a perfectly suitable model for examining the role of protein structural features as opposed to sequence in the selection of peptides and the dominance of certain epitope responses.</p><p>Here, we exploited this model to obtain insights into the selection of CD4 T cell epitopes in WN virus infection. By measuring responses in 29 individuals with either West Nile virus disease (WND) or asymptomatic infection, we identified 67 peptides in the viral capsid and envelope proteins that were recognized in the context of multiple different HLA II alleles. Although WND patients and asymptomatic subjects displayed differences with respect to the recognition of certain epitopes associated with specific HLA alleles, the overall epitope patterns between these groups were similar. Both in C and E proteins, immunodominant epitopes clustered in structurally conserved regions that have also been identified as frequent targets in other mosquito-borne flaviviruses. These data are consistent with an important influence of conserved conformational features in the structural proteins of flaviviruses that shape the specificities and immunodominance of CD4 T cell responses.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec><title>Study Population</title><p>A total of 29 WN virus-infected subjects were enrolled in this study (<xref rid="T1" ref-type="table">Table 1</xref>). The cohort consisted of 11 WND patients (age range, 27&#x02013;65 years; median age, 51 years; 4 female and 7 male) with moderate to severe symptoms (<xref rid="T1" ref-type="table">Table 1</xref>), as well as 18 asymptomatic blood donors (age range, 34&#x02013;70 years; median age, 55 years; 3 female and 15 male) who were recruited through routine screening of blood donations performed by the Austrian Red Cross and the Regional Reference Laboratory of the Lombardy Region (Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo Pavia) in northern Italy.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of West Nile virus-infected subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="left" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Diagnosis of WNV infection</bold></th><th valign="top" align="left" colspan="3" style="border-bottom: thin solid #000000;" rowspan="1"><bold>IL-2 ELISPOT result</bold></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Patient</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symptoms</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>WNV RNA<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>WNV</bold><break/>
<bold>IgM</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>E</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>prM</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>C</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">501</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">37</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">502</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">503</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">113</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">48</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">504</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">505</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">43</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">506</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">507</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, muscle aches</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">508</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">509</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">99</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">22</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">510</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, fatigue, muscle aches</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">511</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">neg</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">512</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, headache</td><td valign="top" align="left" rowspan="1" colspan="1">neg</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">88</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">513</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, headache, rash</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">53</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">514</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">515</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">81</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">42</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">516</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">53</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">517</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">30</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">518</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, ocular pain</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">519</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, encephalitis</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">225</td><td valign="top" align="center" rowspan="1" colspan="1">108</td><td valign="top" align="center" rowspan="1" colspan="1">175</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">520</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">neg</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">521</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">151</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">522</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">149</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">523</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">63</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">43</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">524</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, muscle aches, ocular pain</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">90</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">525</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, fatigue, vertigo, nystagmus</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">69</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">526</td><td valign="top" align="left" rowspan="1" colspan="1">Fever, rash, muscle aches, fatigue</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">128</td><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="center" rowspan="1" colspan="1">73</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">701</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic (fatigue)</td><td valign="top" align="left" rowspan="1" colspan="1">neg</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">705</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">712</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">pos</td><td valign="top" align="left" rowspan="1" colspan="1">Pos</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>a</label><p><italic>WN virus PCR performed in plasma, whole blood, serum and/or cerebral spinal fluid</italic>.</p></fn></table-wrap-foot></table-wrap><p>At the time of diagnosis, 25 out of 29 (86%) individuals had detectable WN virus RNA in blood samples, and 29 out of 29 (100%) had detectable WN virus IgM (<xref rid="T1" ref-type="table">Table 1</xref>). WN virus infection was confirmed in all study participants by neutralization tests, as described below. Previous infection with mosquito-borne flaviviruses from other serocomplexes was analyzed by neutralization assays, as described in detail below. At the time of diagnosis, all 29 participants were negative in Zika neutralization tests. In addition, previous DEN virus infection was ruled out in 28 out of 29 subjects using DEN immunoassays after depletion of broadly flavivirus cross-reactive antibodies, as described below. As a control, samples obtained from 10 flavivirus-na&#x000ef;ve individuals were analyzed.</p></sec><sec><title>Ethics Statement</title><p>The study was performed in accordance with the recommendations of the Declaration of Helsinki, and all study participants provided written informed consent. The ethics committee of the Medical University of Vienna, Austria, approved the study protocol (approval no. 1295/2016). Patient samples were processed in accordance with biosecurity regulations and institutional safety procedures.</p></sec><sec><title>Detection of West Nile Virus RNA</title><p>WN virus PCR was performed as described previously (<xref rid="B31" ref-type="bibr">31</xref>). Briefly, WN virus RNA was extracted from plasma, whole blood, serum and/or cerebral spinal fluid using NucliSENS easyMAG extractor (BioM&#x000e9;rieux, Marcy l'Etoile, France). For the detection of WN virus lineages 1 and 2, a real-time TaqMan PCR with primers and probe located within the conserved WN virus 3&#x02032;-noncoding region was used (<xref rid="B32" ref-type="bibr">32</xref>).</p></sec><sec><title>Detection of West Nile Virus IgM</title><p>WN virus-specific IgM antibodies were detected in a capture ELISA using purified formalin-inactivated WN virus (<xref rid="B31" ref-type="bibr">31</xref>) and a WN virus-specific monoclonal antibody E16 for detection (<xref rid="B33" ref-type="bibr">33</xref>).</p></sec><sec><title>Neutralization Tests</title><p>Neutralization tests (NTs) to confirm WN virus infection were performed with follow-up samples from all individuals, as described previously (<xref rid="B31" ref-type="bibr">31</xref>). Briefly, duplicates of serial 2-fold dilutions of heat-inactivated serum samples were incubated with 30&#x02013;60 TCID<sub>50</sub> (50% tissue culture infective dose) of WN virus strain NY99 for 1 h at 37&#x000b0;C. Vero cells (ECACC) were added and incubation was continued for 4&#x02013;6 days at 37&#x000b0;C. The presence of infectious (non-neutralized) virus was assessed by microscopic evaluation of cytopathic effects. Virus NT titers were expressed as the reciprocal of the serum dilution required for hundred percent protection against virus-induced cytopathic effects. Virus NT titers &#x02265;20 were considered positive. Zika virus-specific neutralizing antibodies were determined in Vero cells (<xref rid="B23" ref-type="bibr">23</xref>). Duplicates of serial 2-fold dilutions of heat-inactivated serum samples were incubated with 30&#x02013;60 TCID<sub>50</sub> Zika virus (strain H/PF 2013) for 1 h at 37&#x000b0;C. Vero cells were added and incubation was continued for 3&#x02013;4 days. Virus NT titers were expressed as the reciprocal of the serum dilution required for hundred percent protection against virus-induced cytopathic effects. Virus NT titers &#x02265;20 were considered positive (<xref rid="B23" ref-type="bibr">23</xref>). YF and TBE NTs were carried out in baby hamster kidney cells (BHK-21, ATCC) (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Duplicates of serial 2-fold dilutions of heat-inactivated serum samples were incubated with YF-17D virus or TBE virus strain Neudoerfl for 1 h at 37&#x000b0;C. BHK cells were added and incubation was continued for 3&#x02013;4 days. YF NT titers were expressed as the reciprocal of the serum dilution required for hundred percent protection against virus-induced cytopathic effects (<xref rid="B23" ref-type="bibr">23</xref>). Virus NT titers &#x02265;20 were considered positive. In the case of TBE, the presence of virus was measured in the supernatants using ELISA. Neutralization titers were defined as the reciprocal of the plasma dilution that gave a 90% reduction in the absorbance readout in the assay compared to the control without antibody (<xref rid="B23" ref-type="bibr">23</xref>). Virus NT titers &#x02265;10 were considered positive. Positive NT titers for YF or TBE or both were obtained in 0 (0%), 21 (72%), and 3 (10%) cases, respectively. Flavivirus-na&#x000ef;ve control samples were negative in neutralization assays. Neutralization assays using infectious virus were performed under biosafety level BSL3.</p></sec><sec><title>Antibody Depletion</title><p>Depletion of cross-reactive antibodies and dengue IgG ELISAs (Euroimmun) were performed to rule out previous DEN virus infection (<xref rid="B23" ref-type="bibr">23</xref>). Broadly cross-reactive antibodies were depleted from serum samples using a strep-tagged soluble E protein (sE, lacking the stem-anchor region) from Rio Bravo virus (<xref rid="B35" ref-type="bibr">35</xref>), coupled to StrepTactin XT spin columns (IBA GmbH, G&#x000f6;ttingen, Germany). Residual DEN-IgG reactivity was below the detection limit in 28 of 29 patients, indicating that they were DEN-na&#x000ef;ve. In the depleted serum of one donor (#705) DEN-IgG Abs were not removed by Rio Bravo virus E protein.</p></sec><sec><title>Preparation of Blood Samples</title><p>Peripheral blood mononuclear cells (PBMCs) were separated from whole-blood samples using Ficoll-Paque Plus&#x02122; (GE Healthcare) and were cryopreserved in liquid nitrogen, as previously described (<xref rid="B23" ref-type="bibr">23</xref>). PBMCs were thawed and depleted of CD8-positive cells using magnetic beads coupled with anti-CD8 antibody and LD columns (Miltenyi Biotec GmbH, Germany), as previously described (<xref rid="B24" ref-type="bibr">24</xref>). The depleted PBMCs were incubated overnight in serum-free medium (AIM-V; Gibco) at 37&#x000b0;C in 5% CO<sub>2.</sub> For use in ELISPOT assays, cells were resuspended at a final concentration of 2 &#x000d7; 10<sup>6</sup> cells/ ml in AIM-V. The purity and viability of CD8-depleted PBMCs in each sample was assessed using anti-CD8-APC, anti-CD3-PE, anti-CD4-PacificBlue&#x02122;, and 7-aminoactinomycin D (BD Bioscience) and flow cytometry (<xref rid="B23" ref-type="bibr">23</xref>). After depletion, CD8-positive cells were &#x0003c;1%. Plasma and serum samples were stored at &#x02212;20&#x000b0;C.</p></sec><sec><title>Peptides</title><p>Peptides were purchased from JPT Peptide Technologies (Berlin, Germany). Peptide purity was &#x0003e;70%. Peptides were quantified and verified for correct sequence by JPT, using high-performance liquid chromatography. The average purity was &#x0003e;85%. Lyophilized peptides were dissolved in dimethyl sulfoxide and diluted in AIM-V medium (<xref rid="B23" ref-type="bibr">23</xref>). A total of 190 peptides (15 mer) overlapping by 11 amino acids which cover the entire sequences of C, prM, and E from the WN virus strain Austria/2008 (protein accession code: <ext-link ext-link-type="PDB" xlink:href="AGX89731">AGX89731</ext-link>). Three master pools covered the C, prM, or E protein sequences. Matrix pools of C (<italic>n</italic> = 10) and E (<italic>n</italic> = 22) contained up to 14 peptides with each peptide present in two distinct pools. All positive results obtained with the matrix pools were confirmed by testing the samples with single peptides in independent experiments.</p></sec><sec><title>IL-2 ELISPOT Assay</title><p>IL-2 ELISPOT assays were performed as previously described (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>). Briefly, plates (Merck-Millipore) were coated with 1 &#x003bc;g anti-IL-2 antibody (3445-3-1000, Mabtech). For blocking, RPMI 1640 medium (Sigma) containing 10% human serum, 1% penicillin/streptomycin/glutamine (Gibco), and 1% non-essential amino acids (Sigma) was used. CD8-depleted PBMCs (2 &#x000d7; 10<sup>5</sup>/ per well) were incubated at 37&#x000b0;C and 5% CO<sub>2</sub> for about 45 h with peptides (final peptide concentration 2 &#x003bc;g/ml), AIM-V medium (negative control) or phytohemagglutinin (PHA, Sigma) (final concentration 0.5 &#x003bc;g/ ml, positive control). After washing, spots were developed with 0.05 &#x003bc;g biotin-conjugated anti-IL-2 antibody (3445-6-250, Mabtech), streptavidin-coupled alkaline phosphatase (ALP; 1:1000, 3310-10, Mabtech), and 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (BCIP/NBT; B5655, Sigma). The plates were analyzed using a Bio-Sys Bioreader 5000 Pro-S/BR177 and Bioreader software generation 10. Data were calculated as spot forming cells (SFCs) per 10<sup>6</sup> CD8-depleted PBMCs after subtraction of the spots from the negative control (mean spot number from three to four unstimulated wells). The response to a single peptide was defined positive if the corresponding master pool, matrix pool as well as single-peptide testing yielded &#x0003e;20 SFCs per 10<sup>6</sup> CD8-depleted PBMCs (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p></sec><sec><title>Structural Analysis and Comparison of Flavivirus Epitopes</title><p>Experimentally identified WN virus epitopes were assigned to the crystallographic or cryo-EM structures of the WN virus sE protein monomer (PDB 2I69) (<xref rid="B25" ref-type="bibr">25</xref>), the Kunjin virus (KUNV) C protein (PDB 1SFK) (<xref rid="B36" ref-type="bibr">36</xref>), as well as the Japanese encephalitis (JE) virus E dimers (PDB 3P54 and 5WSN) (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>) and the St. Louis encephalitis (SLE) virus E trimer (PDB 4FG0) (<xref rid="B39" ref-type="bibr">39</xref>), all belonging to the same serocomplex, using PyMol (Schr&#x000f6;dinger LLC, <ext-link ext-link-type="uri" xlink:href="https://pymol.org/">https://pymol.org/</ext-link>). For comparisons, all epitopes were derived from <italic>ex vivo</italic> ELISPOT assays obtained with human CD4 T cells and peptides that span the entire protein sequences (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Crystallographic structures used for assignment of experimentally identified epitopes were KUN virus C (PDB 1SFK), Zika sE (5LBV) (<xref rid="B26" ref-type="bibr">26</xref>), DEN-2 sE (PDB 1OAN) (<xref rid="B27" ref-type="bibr">27</xref>), and YF sE (PDB 6EPK) (<xref rid="B28" ref-type="bibr">28</xref>). For comparison of all mosquito-borne flavivirus protein sequences and epitopes of C and E, multiple sequence alignments were performed (GenBank: Zika virus <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="KJ776791">KJ776791</ext-link>; DEN 1&#x02013;4 viruses AF226687, M29095, DQ863638, GQ398256; YF virus CAA27332; WN virus DQ211652 and JE virus D90194) using Clustal Omega and manually refined, as described previously (<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>). This analysis also included predicted MHC II-binding peptides derived from DEN virus C or E that were positive in at least two responders (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>), as well as epitopes from the JE virus C and E proteins (<xref rid="B47" ref-type="bibr">47</xref>).</p><p>Structural similarity of the identified epitope regions was assessed using crystallographic structures of the WN virus (PDB 2I69), YF virus (PDB 6EPK), Zika virus (PDB 5LBV), and DEN virus sE proteins (PDB 1OAN) lacking the stem-anchor region. For selected WN virus epitope regions E41, E149, E245, and E381, as well as for the corresponding regions in YF, Zika, and DEN viruses, structural superposition of WN virus sE domains I (E41, E149), II (E245), or III (E381), respectively onto those of YF, Zika and DEN viruses was performed using the PyMOL algorithms &#x0201c;align&#x0201d; and &#x0201c;super&#x0201d; (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Root-mean-square deviation (RMSD) of selected epitope regions was computed through the PyMOL &#x0201c;rms_cur&#x0201d; command (without further fitting).</p></sec><sec><title>HLA Genotyping</title><p>HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 alleles from all study participants were genotyped by sequencing of the whole gene. Genotyping of HLA-DRB3/4/5 allele genotyping was done from exon 2 to the 3&#x02032;UTR by next generation sequencing as described previously (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Briefly, long-range PCR products were generated by allele-specific primers and libraries generated by enzymatic fragmentation of the amplicons. After ligation to barcoded adapters the libraries were subjected to an emulsion PCR and the product sequenced on an Ion Torrent sequencing device (IonTorrent PGM, Thermo Fisher Scientific Inc., Waltham, MA). Sequences were analyzed using HLATypeStream (Thermo Fisher Scientific Inc., Waltham, MA) and NGS GenDX (GenDX, Utrecht, NL) software. HLA genotypes were assigned on basis of the IMGT/HLA database. For HLA-DQ predictions, haplotype compositions of &#x02013;DQA1 and &#x02013;DQB1 were assigned, based on the strongest linkage between these alleles, according to the reference HLA haplotype frequency standards (<xref rid="B51" ref-type="bibr">51</xref>).</p></sec><sec><title><italic>In silico</italic> Prediction of MHC II Binding</title><p>Predictions were done in July 2019 using the Immune Epitope Database (IEDB) analysis tools &#x0201c;IEDB recommended&#x0201d; (<ext-link ext-link-type="uri" xlink:href="http://www.iedb.org">www.iedb.org</ext-link>) and &#x0201c;NetMHCIIpan&#x0201d; (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). C and E protein sequences of WN virus (protein accession code: <ext-link ext-link-type="PDB" xlink:href="AGX89731">AGX89731</ext-link>) were entered separately. Predictions were done for all experimentally tested peptides and the HLA class II alleles from all individuals (<xref ref-type="supplementary-material" rid="SM1">Table S2</xref>). For individual predictions, query submission was automated using the framework provided by the PeptX project (<xref rid="B54" ref-type="bibr">54</xref>).</p></sec><sec><title>Data Analysis</title><p>Statistical analyses were performed with GraphPad Prism, version 5. Comparisons of overall CD4 T cell reactivity in asymptomatic donors and WND patients was done using a non-parametric Kruskal-Wallis test. A Wilcoxon-signed rank test was used for comparison of the number of peptides that induced a response in asymptomatic donors and WND patients. A Spearman correlation coefficient was calculated for evaluation of two-by-two correlations. The strength of associations between expression of a specific allele and detection of a positive epitope response was calculated as described previously (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Briefly, odds ratios (ORs) were calculated, according to the following formula: <italic>OR</italic> = <inline-formula><mml:math id="M1"><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>R</mml:mi><mml:mo>+</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mo>-</mml:mo><mml:mi>R</mml:mi><mml:mo>-</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mo>-</mml:mo><mml:mi>R</mml:mi><mml:mo>+</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>R</mml:mi><mml:mo>-</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></inline-formula>.</p><p><italic>A</italic>+<italic>R</italic>+ = number of subjects who expressed the specific allele and had a positive response to the specific peptide, <italic>A</italic>+<italic>R</italic>&#x02212; = number of subjects who expressed the specific allele but did not have a positive response to the specific peptide, <italic>A</italic>&#x02212;<italic>R</italic>+ = number of subjects who did not express the specific allele but had a positive response to the specific peptide, <italic>A</italic>&#x02212;<italic>R</italic>&#x02212; = number of subjects who did not express the specific allele and did not have a positive response to the specific peptide (<xref rid="B56" ref-type="bibr">56</xref>). Fisher's exact test was applied to calculate the statistical significance of the association between one or more specific HLA alleles and the response to a specific peptide (<xref rid="B55" ref-type="bibr">55</xref>). A <italic>p</italic>-value &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>CD4 T Cell Response Against WN Virus Structural Proteins</title><p>We first investigated the overall reactivity of CD4 T cell responses to peptides derived from the WN virus structural proteins, the capsid C, membrane prM/M and envelope E (<xref ref-type="fig" rid="F1">Figure 1A</xref>). PBMC samples from WN virus-infected individuals were depleted of CD8-positive cells and tested in IL-2 ELISPOT assays with pools of overlapping 15 mer peptides that cover the entire sequence of each of the structural proteins. The study population consisted of 29 subjects (18 asymptomatic/11 WND patients; age range 27&#x02013;70 years) (<xref rid="T1" ref-type="table">Table 1</xref>), recruited at a mean of 40 &#x000b1; 6 days after diagnosis. In terms of the overall magnitude, highest responses were elicited by E peptides, which accounted for 57% of the total response, followed by C and prM peptides, which accounted for 29 and 14% of the total response, respectively (<xref ref-type="fig" rid="F1">Figures 1B,C</xref>). In contrast, none of the flavivirus-na&#x000ef;ve individuals showed a response to any of the C, prM and E peptides, confirming the specificity of this assay (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p><p>To determine the epitope specificities of responses, we performed IL-2 ELISPOT assays using peptide matrix pools and single peptides covering the entire C and E proteins. As observed for other flaviviruses (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>), the prM peptides yielded only weak positive signals (<xref ref-type="fig" rid="F1">Figure 1B</xref>), and therefore single peptide analysis was not performed. On average, individual responses were directed against five CD4 T cell epitopes accounting for a median 148 spot forming cells (SFCs) (range, 31&#x02013;414 SFCs). There were no significant differences in the breadth or magnitude of responses between WND patients (median, 6.0 epitopes; 205 SFCs, range: 88&#x02013;414) and asymptomatic subjects (median, 3.5 epitopes, 94.5 SFCs, range: 31&#x02013;412). The cumulative number of spots for each peptide, using the results from all subjects obtained with the single-peptide testing, is displayed in <xref ref-type="fig" rid="F2">Figure 2A</xref>. Individuals with asymptomatic infection and WND yielded similar epitope response patterns (<italic>p</italic> &#x0003c; 0.0001, Spearman correlation <italic>r</italic> = 2.8) (<xref ref-type="supplementary-material" rid="SM1">Figure S1</xref>). Overall, we identified 61 peptides that induced a CD4 T cell response, indicating a substantial heterogeneity in the individual epitope reactivities (<xref ref-type="supplementary-material" rid="SM1">Table S1</xref>). However, closer inspection of the data showed that few epitopes accounted for the majority of the response. These epitopes, recognized in two or more individuals, accounted for 50% of the total SFC responses and were defined as immunodominant. The immunodominant peptides clustered in two antigenic regions of C (C41 and C73) and in eight regions of E (E41, E125, E149, E205, E245, E325, E381, and E417) (<xref ref-type="fig" rid="F2">Figure 2A</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Mapping of CD4 T Cell Epitopes to WN Virus C and E Proteins. <bold>(A)</bold> Total spot counts of positive responses to single peptides. Amino acid positions of peptides in C and E protein sequences are indicated on the x-axes. Peptides recognized in two or more individuals are indicated by asterisks and are designated by the first amino acid of the 15 mer peptide. <bold>(B)</bold> Ribbon diagram of the WN virus lineage 1 variant Kunjin C protein (PDB 1SFK) (<xref rid="B36" ref-type="bibr">36</xref>), comprising four helices (H1-H4). <bold>(C)</bold> Ribbon representation of the WN virus soluble E (sE) ectodomain (PDB 2I69; side view) (<xref rid="B25" ref-type="bibr">25</xref>), consisting of three domains (DI-DIII). <bold>(D)</bold> Surface representation of the Japanese encephalitis virus pre-fusion sE dimer (top view, PDB 3P54) (<xref rid="B37" ref-type="bibr">37</xref>) and the full-length E dimer (side view, PDB 5WSN) (<xref rid="B38" ref-type="bibr">38</xref>). <bold>(E)</bold> Surface depiction of the St. Louis encephalitis virus post-fusion E protein trimer (PDB 4FG0; side view) (<xref rid="B39" ref-type="bibr">39</xref>); the unresolved stem is added schematically to the structure and shown as dotted line along domain II (purple). Immunodominant WN virus peptides are colored as follows: C, green; E, DI-red, DII-yellow, DIII-blue, and stem-purple.</p></caption><graphic xlink:href="fimmu-11-00016-g0002"/></fig></sec><sec><title>Structural Analysis of Immunodominant Sites in C and E Proteins</title><p>Since the structural context of an epitope has been proposed to influence immunodominance (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>), we next analyzed the structural characteristics of the protein regions from which the identified epitopes were derived. For this purpose, we mapped the immunodominant epitopes on the three-dimensional structures of the WN virus C and E proteins. As illustrated in <xref ref-type="fig" rid="F2">Figure 2B</xref>, responses to the C protein were mainly focused to helices H2 and H4, whereas helices H1, H3, and the N-terminal part of C did not elicit dominant responses. In the E protein (<xref ref-type="fig" rid="F2">Figure 2C</xref>), immunodominant epitopes clustered in each of the three domains [three in domain I (E41, E125, and E149), two in domain II (E205 and E245), two in domain III (E325, E381)] and in the stem region (E417). As shown in <xref ref-type="fig" rid="F2">Figures 2D,E</xref>, epitopes from all three domains were located at the outside of the E protein in its dimeric conformation as well as in its trimeric form. In addition, the trimer exposes an epitope (E417) in the stem region (<xref ref-type="fig" rid="F2">Figure 2E</xref>), whereas the stem is hidden below the E ectodomain in its pre-fusion conformation (<xref ref-type="fig" rid="F1">Figures 1A</xref>, <xref ref-type="fig" rid="F2">2D</xref>).</p><p>We next compared the experimentally identified WN virus epitopes with the epitopes previously determined for other mosquito-borne flaviviruses, including YF, Zika, and DEN viruses. All of these epitopes were identified in <italic>ex vivo</italic> ELISPOT testing of human CD4 T cells and overlapping peptides covering the entire protein sequences (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). As can be seen in <xref ref-type="fig" rid="F3">Figure 3A</xref>, immunodominant regions in C were uniformly located at positions in helices H2 and H4 (C41, C73). In E (<xref ref-type="fig" rid="F3">Figure 3B</xref>), three of the dominant WN virus epitopes (E41, E245, and E381) mapped to sites harboring immunodominant epitopes in all mosquito-borne flaviviruses, except for E381, which was not identified in DEN virus infections. Structurally, these common epitope regions encompassed &#x000df;-sheets as well as loops that are about 20 amino acids long and are devoid of disulphide bridges (<xref ref-type="fig" rid="F3">Figure 3B</xref>). In addition, we identified two dominant sites (E125 and E205) that were congruent between WN, Zika, and DEN viruses. These data together with all epitopes identified by <italic>ex vivo</italic> ELISPOT assays are shown in <xref ref-type="supplementary-material" rid="SM1">Figure S2</xref>. Two WN virus epitopes (E325 and E417) were not present in DEN, Zika, and YF viruses, but overlapped with those previously identified in Japanese encephalitis virus, a closely related flavivirus of the same serocomplex (<xref ref-type="supplementary-material" rid="SM1">Figure S2</xref>). In contrast, one epitope, E149, which involves an extra &#x003b1;-helix in DI, was only found in WN virus (<xref ref-type="supplementary-material" rid="SM1">Figure S2</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Comparison of CD4 T Cell Epitope Sites in C and E Proteins of Mosquito-borne Flaviviruses. <bold>(A)</bold> Ribbon representation of the flavivirus Kunjin C protein (PDB 1SFK) (<xref rid="B36" ref-type="bibr">36</xref>) highlighting epitopes recognized in WN, Zika (<xref rid="B23" ref-type="bibr">23</xref>), DEN (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>), and YF viruses (<xref rid="B22" ref-type="bibr">22</xref>). <bold>(B)</bold> Envelope protein structure alignment of WN (PDB 2I69) (<xref rid="B25" ref-type="bibr">25</xref>), Zika (PDB 5LBV) (<xref rid="B26" ref-type="bibr">26</xref>), DEN (PDB 1OAN) (<xref rid="B27" ref-type="bibr">27</xref>), and YF (PDB 6EPK) (<xref rid="B28" ref-type="bibr">28</xref>) viruses with assigned epitopes. Boxes highlight immunodominant epitope regions in each of the viruses. Immunodominant epitopes are colored as follows: C, green; DI-red, DII-yellow, and DIII-blue.</p></caption><graphic xlink:href="fimmu-11-00016-g0003"/></fig><p>As a further estimate for the structural homology of the common flavivirus epitope sites, we computed the RMSD of selected epitope regions after pairwise structural alignments of WN virus sE protein domains with those of YF, Zika and DEN viruses, respectively. The analysis included epitope regions E41, E245, and E381, which were common among flaviviruses (<xref ref-type="fig" rid="F3">Figure 3B</xref>), as well as epitope E149, which had no equivalent in other flaviviruses (<xref ref-type="supplementary-material" rid="SM1">Figure S2</xref>). As can be seen in <xref ref-type="fig" rid="F4">Figure 4</xref>, alignment of sE proteins yielded RMSD values of 2.58&#x02013;3.96&#x000c5;, consistent with those for homologous proteins (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B59" ref-type="bibr">59</xref>). The &#x000df;-sheet encompassing E41 yielded very low RMSD values (0.90&#x02013;1.61 &#x000c5;), and values below 2 &#x000c5; were also observed for all pairwise comparisons of E245 and E381, except for E245 in DEN virus, which had a value of 3.50 to 3.59 &#x000c5;. In contrast, E149 yielded RMSD values of 6.74 to 26.10 &#x000c5;, indicating a structurally divergent region. In fact, in WN virus, this site harbors an extra &#x003b1;-helix protruding from the upper part of E DI, which is absent in Zika and DEN viruses (<xref ref-type="fig" rid="F4">Figure 4</xref>). It is notable that an &#x003b1;-helix occurs at a similar sequence position in the YF virus E protein, however this helix exhibits a ~90&#x000b0; twisted orientation and sticks closer to the surface of E DI (<xref ref-type="fig" rid="F4">Figure 4</xref>). Together, the data suggest that the common epitope sites resulted from conserved structural features that favor their selection across different flaviviruses.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Structural Similarity of Common Flavivirus Epitope Regions in E. Pairwise structural alignments for E proteins between WN virus (PDB 2I69) (<xref rid="B25" ref-type="bibr">25</xref>) and YF (PDB 6EPK) (<xref rid="B28" ref-type="bibr">28</xref>), Zika (PDB 5LBV) (<xref rid="B26" ref-type="bibr">26</xref>), or DEN (PDB 1OAN) (<xref rid="B27" ref-type="bibr">27</xref>) viruses. Structural elements encompassing the selected epitopes were analyzed, using the PyMOL algorithms &#x0201c;align&#x0201d; and &#x0201c;super.&#x0201d; These elements are colored in green (WN virus), yellow (YF virus), purple (Zika virus), and red (DEN virus). RMSD values are given in &#x000c5;ngstr&#x000f6;m.</p></caption><graphic xlink:href="fimmu-11-00016-g0004"/></fig></sec><sec><title>HLA II Binding Prediction and Association of Epitope Responses</title><p>The immunogenicity of CD4 T cell epitopes is also determined by the affinity of a particular peptide to an individual's HLA repertoire. As a prerequisite for MHC II affinity prediction, HLA genotyping of class II alleles (DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1) was performed for each of the 29 donors (<xref ref-type="supplementary-material" rid="SM1">Table S2</xref>). First, HLA binding affinity was predicted for the entire set of experimentally tested WN virus C and E peptides (<italic>n</italic> = 150) using the NetMHCIIpan algorithm provided by the Immune Epitope Database (IEDB). Approximately 1,400 peptide-MHC II pairs yielded IC<sub>50</sub> values of &#x0003c; 500 nM, indicating likely binders (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). Analysis of the data displayed in <xref ref-type="fig" rid="F5">Figure 5A</xref> revealed that 97% of the peptides were predicted with several different HLA alleles (up to 30 different alleles/peptide), and only 3% were predicted exclusively for one or no allele. We therefore conclude that the majority of peptides derived from C and E proteins could theoretically be presented by a large number of different MHC molecules expressed in this study cohort. However, a considerable number of frequently predicted peptides did not elicit a dominant CD4 T cell response in ELISPOT assays. This was especially the case for peptides derived from the transmembrane anchors (aa 449-501), as well as for peptides from domains II (aa 261-295) and III (aa 349-375) (<xref ref-type="fig" rid="F5">Figure 5A</xref>). These findings are consistent with the notion that HLA binding is a necessary but not sufficient requirement for T cell responses (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Peptide-MHC II Binding Prediction and HLA Association of West Nile Virus Epitopes. <bold>(A)</bold> Predicted IC<sub>50</sub> values for experimentally tested peptides and the HLA II alleles of the study cohort. Peptides with the highest affinities locate toward the bottom of the y-axes and have IC<sub>50</sub> values below 500 nM (dotted line). <bold>(B)</bold> The chord diagram demonstrates for each individual, the experimentally identified epitope on the left side of the circle, connected with the HLA II allele predicted with best percentile rank on the right side of the circle. Immunodominant peptides are in bold. <bold>(C)</bold> Chord diagram indicating HLA II alleles associated with immunodominant epitopes in C and E. Epitopes detected only in asymptomatic individuals are indicated by asterisks. Epitope sequences previously identified by HLA II tetramer staining (<xref rid="B60" ref-type="bibr">60</xref>) are underlined.</p></caption><graphic xlink:href="fimmu-11-00016-g0005"/></fig><p>In addition to this population-based approach, we assessed specifically for each individual which of the HLA alleles had the best prediction value (best percentile rank) for the peptides detected in ELISPOT assays, using the Immune Epitope Database (IEDB) analysis tool &#x0201c;IEDB recommended&#x0201d; (<ext-link ext-link-type="uri" xlink:href="http://www.iedb.org">www.iedb.org</ext-link>). In this analysis, 82% of all experimentally identified peptides had an IEDB percentile rank of &#x02264;20 for the individual HLA II alleles. For the illustration of the results in <xref ref-type="fig" rid="F5">Figure 5B</xref>, a chord diagram was used which presents all experimentally identified epitopes on the left side of the circle, connected to the HLA II alleles predicted with best percentile ranks on the right side of the circle. Notably, more than 50% of the immunodominant peptides were predicted to bind quite strongly, with percentile ranks &#x0003c;1.5, and 90% with percentile ranks &#x0003c;10 (<xref ref-type="supplementary-material" rid="SM1">Table S3</xref>). These data indicate that most of the immunodominant epitopes were predicted as strong binders.</p><p>To assess the strength of association between a particular HLA allele and the epitope response in each individual, we calculated odds ratios (ORs) for all combinations of HLA alleles and dominant peptides shown in <xref ref-type="fig" rid="F5">Figure 5B</xref>. In the case of peptides predicted as binders for more than one HLA allele, combined calculations for these alleles were performed, as described previously (<xref rid="B55" ref-type="bibr">55</xref>). Evidence for significant associations with specific HLA alleles were obtained for most but not all immunodominant peptides (<xref ref-type="supplementary-material" rid="SM1">Table S3</xref> and <xref ref-type="fig" rid="F5">Figure 5C</xref>). The data show that, while only 25% (3/12) of these epitopes were associated with one single HLA allele (C41-DRB4<sup>*</sup>01:03, C73-DRB5<sup>*</sup>01:01 and E381-DRB1<sup>*</sup>11:01), 75% (9/12) were associated with two to four different HLA molecules (<xref ref-type="fig" rid="F5">Figure 5C</xref>). These findings indicate that most immunodominant WN virus epitopes are recognized in the context of different HLA molecules, consistent with the well-known phenomenon of promiscuous binding of immunogenic peptides (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>). The data also corroborate previous results obtained with tetramers using different HLA-DR molecules (<xref rid="B60" ref-type="bibr">60</xref>) which match almost half of the C and E peptides identified in the present study (peptide matches are underlined in <xref ref-type="fig" rid="F5">Figure 5C</xref>). The OR calculations were also applied to asymptomatic or WND subjects separately. Three of the epitopes yielded a significant HLA association in asymptomatic donors but not in WND patients. These epitopes (E41-IDVKMMNMEAANLAD-HLA-DRB1<sup>*</sup>01:02 and -DRB1<sup>*</sup>04:01 [<italic>p</italic> = 0.039; OR 29.0], E381-DSYIVVGRGEQQINH-HLA-DRB1<sup>*</sup>11:01 [<italic>p</italic> = 0.0196; OR 51.7] and E433-GVFTSVGKAIHQVFG-HLA-DRB1<sup>*</sup>07:01 [<italic>p</italic> = 0.039; OR 29.0]) were detected experimentally only in asymptomatic but in none of the WND subjects and are indicated by asterisks in <xref ref-type="fig" rid="F5">Figure 5C</xref>.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Factors responsible for controlling the immunodominance of certain epitope sites of viral proteins in CD4 T cell responses are poorly defined but can be of great importance for generating protective immunity. A better understanding of these fundamentals requires unbiased exploration of the <italic>ex vivo</italic> T cell epitope repertoire, defining the structural features and the host genetic factors that underlie the preferential selection of epitopes. Toward these objectives, we examined the CD4 T cell epitope specificities in 29 WN virus-infected individuals, using a library of overlapping peptides covering the entire virion proteins. We focused on CD4 T cells directed against epitopes within the virus structural proteins, because these can mediate help to B cells by direct cell-cell interactions and are therefore essential for the production of neutralizing antibodies, the major protective correlate in flavivirus infections (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Our study demonstrates that dominant CD4 T helper cell responses are directed to two helices in the virus capsid and to surface-exposed regions of the viral envelope protein E in its pre- and post-fusion forms. This immunodominance pattern was strikingly similar to those previously identified for distantly related flaviviruses, including Zika (<xref rid="B23" ref-type="bibr">23</xref>), DEN (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>), and YF (<xref rid="B22" ref-type="bibr">22</xref>) viruses. Especially with epitopes of the capsid protein, the immunodominance patterns were remarkably similar for each of the different flaviviruses. Also in the case of E, we observed a strong overlap of specific epitope regions, particularly with respect to three epitope sites (E41, E245, and E381) that were almost uniformly present in the flaviviruses examined. In our study, epitope reactivities of WN virus-specific CD4 T cells were determined in an <italic>ex vivo</italic> ELISPOT assay using IL-2 that has been applied in a number of previous studies investigating flavivirus-specific CD4 T cell responses (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B65" ref-type="bibr">65</xref>). It was shown that most of the peptide-specific CD4 T cells are polyfunctional (e.g., triple- [IL-2<sup>+</sup>TNF-&#x003b1;<sup>+</sup>IFN-&#x003b3;<sup>+</sup>] or dual-positive [IL-2<sup>+</sup>IFN-&#x003b3;<sup>+</sup>]) cells with at least as many CD4 T cells secreting IL-2 as compared to IFN-&#x003b3; (<xref rid="B65" ref-type="bibr">65</xref>). Consistent with these findings, the present analysis revealed similar distributions of epitopes that were identified using IL-2 (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>) or IFN-&#x003b3; ELISPOT assays (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). However, we cannot exclude that our approach could miss epitopes targeted by single IFN-&#x003b3; positive cells. Further studies that involve dual IFN-&#x003b3; and IL-2 ELISPOT testing will be required to address this issue.</p><p>Analyses in the context of the atomic structures of the corresponding E proteins showed that the common epitopes are displayed in structurally conserved elements and preferentially locate to surface-exposed regions of E (e.g., the domain I-II hinge regions [E41 and E125] as well as the lateral ridge of domain III [E325 and E381]) which have been shown to be important sites for potent neutralizing antibodies against WN virus in humans (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Our findings are consistent with previous studies demonstrating that CD4 T cell epitopes are preferentially located at exposed protein sites or at flanks of conformationally flexible loops (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Such segments may offer initial cleavage sites for proteolytic processing and are easily accessible binding sites for MHC II molecules (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B70" ref-type="bibr">70</xref>). Interestingly, the only immunodominant WN virus epitope (E149) that had no overlap with epitopes from other flaviviruses, included an &#x003b1;-helix that is absent from Zika and DEN viruses. Its protrusion from the upper part of DI may increase its accessibility for proteolytic processing and/or MHC binding. Further evidence for the structural influence on epitope selection was obtained by our finding that several peptides predicted to bind a considerable number of HLA molecules were not observed experimentally. This is especially true for peptides from the transmembrane region that are shielded in the lipid bilayer, which might impose strong constraints on peptide generation (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>In contrast to the other WN virus epitopes identified, the E417 epitope appears to be less accessible in the context of mature virions, because it is sandwiched between the external protein shell and the lipid membrane (<xref ref-type="fig" rid="F1">Figure 1A</xref>). However, upon endocytosis and encounter of the acidic pH in the endosome, flavivirus E proteins undergo a fusogenic conformational change from dimers to trimers, in which the stem is located at the outside (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Since fusion can already occur at the pH of early endosomes (<xref rid="B71" ref-type="bibr">71</xref>), the post-fusion conformation may be an important substrate for generating peptides of the stem region. Such structural aspects may also explain previous observations with TBE virus, which demonstrated that epitopes derived from the stem are immunodominant only in naturally infected patients but not in those vaccinated with a formalin-inactivated vaccine, in which the prefusion conformation of E is stabilized by formaldehyde cross-linking (<xref rid="B24" ref-type="bibr">24</xref>). There are many other well-known examples, such as influenza virus or HIV, which undergo conformational changes that may play a role in the preferential selection of certain epitopes. Moreover, studies with influenza virus reported that some peptides are generated only during protein synthesis in infected cells but not upon exogenous uptake of the same antigen (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B72" ref-type="bibr">72</xref>).</p><p>In addition to protein structure-specific factors that are responsible for characteristic immunodominance patterns, our ELISPOT data revealed considerable individual variation in epitope specificities, indicating additional influences of individual-specific factors that control epitope recognition. Evaluations based on <italic>in silico</italic> predicted peptide-MHC II affinities provide evidence that most immunodominant peptides were predicted as strong binders and could potentially be presented in combination with multiple different MHC II molecules. Our results are consistent with recent studies (<xref rid="B60" ref-type="bibr">60</xref>), demonstrating that CD4 T cells could be detected in direct <italic>ex vivo</italic> samples by peptide-matched tetramers, which included a number of different alleles. Comparing the characteristics of WN virus-specific CD4 T cells in individuals with either neuroinvasive disease or asymptomatic infection, the same study found that individuals with neuroinvasive disease had higher numbers of virus-specific CD4 T cells (<xref rid="B60" ref-type="bibr">60</xref>). This is consistent with the finding that the only patient in our study with neuroinvasive disease (patient #519) demonstrated a substantially higher magnitude of response than other patients, which could be an effect of increased viral replication and/or delayed viral clearance, as described in a significant percentage of patients with WN virus encephalitis (<xref rid="B73" ref-type="bibr">73</xref>). Apart from this single case and in line with previous findings (<xref rid="B74" ref-type="bibr">74</xref>), we observed no differences with respect to the overall magnitude of response between individuals with WND or asymptomatic infection, and no difference was apparent in the breadth of responses among these groups.</p><p>Despite the overall similarities of epitope responses between asymptomatic subjects and WND patients, we did observe certain peptide-HLA combinations which only occurred in asymptomatic individuals. It is unclear at present whether these differences relate to the presence of alleles that protect from WND. An HLA-specific association for both protection and susceptibility to WND was suggested in previous studies (<xref rid="B75" ref-type="bibr">75</xref>&#x02013;<xref rid="B77" ref-type="bibr">77</xref>). Additional research is needed to clarify whether such differences could discriminate patients with different disease outcomes. Knowledge of the immunodominant epitopes displayed by such alleles could substantially contribute to our understanding of the determinants that impact the clinical outcome of infection and the efficacy of vaccines.</p><p>In summary, we have demonstrated that WN virus infection elicits CD4 T cell responses to peptides that cluster in specific regions of the viral structural proteins and are frequently predicted as strong binders for individual HLA alleles. The immunodominant epitopes locate to structurally conserved antigen regions which are also frequently targeted in other clinically relevant flaviviruses, including yellow fever, dengue and Zika viruses. Together, these data provide novel insights into a key aspect of flavivirus immunity, namely how virion protein structure shapes CD4 T cell responses, which is an important issue to consider in rational vaccine design.</p></sec><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>All datasets generated for this study are included in the article/<xref ref-type="sec" rid="s8">Supplementary Material</xref>.</p></sec><sec id="s6"><title>Ethics Statement</title><p>The studies involving human participants were reviewed and approved by the Ethics committee of the Medical University of Vienna, Austria. The patients/participants provided their written informed consent to participate in this study.</p></sec><sec id="s7"><title>Author Contributions</title><p>MK, JA, FH, SA, KS, and SM performed experiments, reviewed data, and planned experimental strategy. BK, MK, FS, and DF performed bioinformatic analysis. GF and IF performed and coordinated HLA typing. FB, IC, HL, and CJ collected samples and provided clinical information. JA and FH conceived the study. JA wrote the first draft. FH and MK contributed to the writing of the manuscript. All authors critically read and edited the manuscript.</p><sec><title>Conflict of Interest</title><p>BK was employed by company Symptoma GmbH, Vienna, Austria. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank Jutta Hutecek, Silvia Schw&#x000f6;diauer, Ursula Sinzinger, and Walter Holzer for excellent technical assistance. We thank Michael S. Diamond for providing the monoclonal antibody E16.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was funded by research grants from the Austrian Science Fund FWF (JA: P29881-B30; KS: P29928-B30).</p></fn></fn-group><sec sec-type="supplementary-material" id="s8"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.00016/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.00016/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>JA</given-names></name><name><surname>Barrett</surname><given-names>ADT</given-names></name></person-group>. <article-title>Twenty years of progress toward west nile virus vaccine development</article-title>. <source>Viruses</source>. (<year>2019</year>) <volume>11</volume>:<fpage>E823</fpage>. <pub-id pub-id-type="doi">10.3390/v11090823</pub-id><?supplied-pmid 31491885?><pub-id pub-id-type="pmid">31491885</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Kolodziejek</surname><given-names>J</given-names></name><name><surname>Jungbauer</surname><given-names>C</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Zoufaly</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increase in human West Nile and Usutu virus infections, Austria, 2018</article-title>. <source>Eurosurveillance</source>. (<year>2018</year>) <volume>23</volume>:<fpage>7</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2018.23.43.1800545</pub-id><?supplied-pmid 30376913?><pub-id pub-id-type="pmid">30376913</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>ADT</given-names></name></person-group>. <article-title>West Nile in Europe: an increasing public health problem</article-title>. <source>J Travel Med.</source> (<year>2018</year>) <volume>25</volume>:<fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1093/jtm/tay096</pub-id><?supplied-pmid 30289526?><pub-id pub-id-type="pmid">30289526</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>LH</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name></person-group>. <article-title>West Nile virus: a growing concern?</article-title>
<source>J Clin Invest</source>. (<year>2004</year>) <volume>113</volume>:<fpage>1102</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1172/JCI21623</pub-id><?supplied-pmid 15085186?><pub-id pub-id-type="pmid">15085186</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="webpage"><source>West Nile Virus-Symptoms Diagnosis and Treatment</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/westnile/symptoms/index.html">https://www.cdc.gov/westnile/symptoms/index.html</ext-link> (accessed October 8, 2019).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name></person-group>. <article-title>The structural immunology of antibody protection against West Nile virus</article-title>. <source>Immunol Rev</source>. (<year>2008</year>) <volume>225</volume>:<fpage>212</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00676.x</pub-id><?supplied-pmid 18837784?><pub-id pub-id-type="pmid">18837784</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehlhop</surname><given-names>E</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group>. <article-title>The molecular basis of antibody protection against West Nile Virus</article-title>. <source>Hum Antibody Therapeut Viral Disease</source>. (<year>2008</year>) <volume>317</volume>:<fpage>125</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-72146-8_5</pub-id><?supplied-pmid 17990792?><pub-id pub-id-type="pmid">17990792</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Kuhn</surname><given-names>RJ</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group>. <article-title>Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development</article-title>. <source>Cell Host Microbe</source>. (<year>2008</year>) <volume>4</volume>:<fpage>229</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2008.08.004</pub-id><?supplied-pmid 18779049?><pub-id pub-id-type="pmid">18779049</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brien</surname><given-names>JD</given-names></name><name><surname>Uhrlaub</surname><given-names>JL</given-names></name><name><surname>Nikolich-Zugich</surname><given-names>J</given-names></name></person-group>. <article-title>West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection</article-title>. <source>J Immunol</source>. (<year>2008</year>) <volume>181</volume>:<fpage>8568</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.12.8568</pub-id><?supplied-pmid 19050276?><pub-id pub-id-type="pmid">19050276</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitati</surname><given-names>EM</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group>. <article-title>CD4(+) T-cell responses are required for clearance of West Nile virus from the central nervous system</article-title>. <source>J Virol</source>. (<year>2006</year>) <volume>80</volume>:<fpage>12060</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01650-06</pub-id><?supplied-pmid 17035323?><pub-id pub-id-type="pmid">17035323</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>K</given-names></name><name><surname>Allison</surname><given-names>SL</given-names></name><name><surname>Schalich</surname><given-names>J</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>Proteolytic activation of tick-borne encephalitis virus by furin</article-title>. <source>J Virol</source>. (<year>1997</year>) <volume>71</volume>:<fpage>8475</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.71.11.8475-8481.1997</pub-id><?supplied-pmid 9343204?><pub-id pub-id-type="pmid">9343204</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group>
<article-title>Viral membrane fusion</article-title>. <source>Virology</source>. (<year>2015</year>) <fpage>479</fpage>&#x02013;<lpage>80</lpage>:498&#x02013;507. <pub-id pub-id-type="doi">10.1016/j.virol.2015.03.043</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Fritz</surname><given-names>R</given-names></name><name><surname>Pangerl</surname><given-names>K</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>Molecular mechanisms of flavivirus membrane fusion</article-title>. <source>Amino Acids</source>. (<year>2011</year>) <volume>41</volume>:<fpage>1159</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1007/s00726-009-0370-4</pub-id><?supplied-pmid 19882217?><pub-id pub-id-type="pmid">19882217</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Sadegh-Nasseri</surname><given-names>S</given-names></name></person-group>. <article-title>Determinants of immunodominance for CD4 T cells</article-title>. <source>Curr Opin Immunol.</source> (<year>2015</year>) <volume>34</volume>:<fpage>9</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2014.12.005</pub-id><?supplied-pmid 25576665?><pub-id pub-id-type="pmid">25576665</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>GX</given-names></name><name><surname>Steede</surname><given-names>NK</given-names></name><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120</article-title>. <source>J Biol Chem</source>. (<year>2001</year>) <volume>276</volume>:<fpage>41913</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M106018200</pub-id><?supplied-pmid 11551929?><pub-id pub-id-type="pmid">11551929</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>SJ</given-names></name><name><surname>Moss</surname><given-names>DL</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Ferrie</surname><given-names>RP</given-names></name><name><surname>Fullerton</surname><given-names>ML</given-names></name><name><surname>Wells</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>Structural basis for CD4+ T cell epitope dominance in arbo-flavivirus envelope proteins: a meta-analysis</article-title>. <source>Viral Immunol.</source> (<year>2017</year>) <volume>30</volume>:<fpage>479</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2017.0008</pub-id><?supplied-pmid 28614011?><pub-id pub-id-type="pmid">28614011</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>Three-dimensional structure determines the pattern of CD4(+) T-cell epitope dominance in influenza virus hemagglutinin</article-title>. <source>J Virol</source>. (<year>2008</year>) <volume>82</volume>:<fpage>1238</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02026-07</pub-id><?supplied-pmid 18057238?><pub-id pub-id-type="pmid">18057238</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mirano-Bascos</surname><given-names>D</given-names></name><name><surname>Tary-Lehmann</surname><given-names>M</given-names></name><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120</article-title>. <publisher-loc>European</publisher-loc>
<source>J Immunol</source>. (<year>2008</year>) <volume>38</volume>:<fpage>1231</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200738011</pub-id><?supplied-pmid 18398933?><pub-id pub-id-type="pmid">18398933</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmicle</surname><given-names>S</given-names></name><name><surname>Steede</surname><given-names>NK</given-names></name><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>Antigen three-dimensional structure guides the processing and presentation of helper T-cell epitopes</article-title>. <source>Mol Immunol</source>. (<year>2007</year>) <volume>44</volume>:<fpage>1159</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2006.06.014</pub-id><?supplied-pmid 16893568?><pub-id pub-id-type="pmid">16893568</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenlohr</surname><given-names>LC</given-names></name><name><surname>Luckashenak</surname><given-names>N</given-names></name><name><surname>Apcher</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Sinnathamby</surname><given-names>G</given-names></name></person-group>. <article-title>Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways</article-title>. <source>Immunol Res</source>. (<year>2011</year>) <volume>51</volume>:<fpage>237</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-011-8257-3</pub-id><?supplied-pmid 22101673?><pub-id pub-id-type="pmid">22101673</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Koblischke</surname><given-names>M</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name></person-group>. <article-title>CD4 T cell responses to flaviviruses</article-title>. <source>J Clin Virol</source>. (<year>2018</year>) <volume>108</volume>:<fpage>126</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2018.09.020</pub-id><?supplied-pmid 30312909?><pub-id pub-id-type="pmid">30312909</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koblischke</surname><given-names>M</given-names></name><name><surname>Mackroth</surname><given-names>MS</given-names></name><name><surname>Schwaiger</surname><given-names>J</given-names></name><name><surname>Fae</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>8907</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-09331-w</pub-id><?supplied-pmid 28827760?><pub-id pub-id-type="pmid">28827760</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koblischke</surname><given-names>M</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Malafa</surname><given-names>S</given-names></name><name><surname>Tsouchnikas</surname><given-names>G</given-names></name><name><surname>Schwaiger</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Structural influence on the dominance of virus-specific CD4 T cell epitopes in Zika virus infection</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>2083</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.02083</pub-id><pub-id pub-id-type="pmid">30254648</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwaiger</surname><given-names>J</given-names></name><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Knapp</surname><given-names>B</given-names></name><name><surname>Schreiner</surname><given-names>W</given-names></name><name><surname>Fae</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Specificities of human CD4(+) T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: correlation with Structure and Epitope Prediction</article-title>. <source>J Virol</source>. (<year>2014</year>) <volume>88</volume>:<fpage>7828</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00196-14</pub-id><?supplied-pmid 24789782?><pub-id pub-id-type="pmid">24789782</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>R</given-names></name><name><surname>Kar</surname><given-names>K</given-names></name><name><surname>Anthony</surname><given-names>K</given-names></name><name><surname>Gould</surname><given-names>LH</given-names></name><name><surname>Ledizet</surname><given-names>M</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes</article-title>. <source>J Virol</source>. (<year>2006</year>) <volume>80</volume>:<fpage>11000</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01735-06</pub-id><?supplied-pmid 16943291?><pub-id pub-id-type="pmid">16943291</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Rouvinski</surname><given-names>A</given-names></name><name><surname>Vaney</surname><given-names>MC</given-names></name><name><surname>Edits</surname><given-names>IM</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Structural basis of potent Zika-dengue virus antibody cross-neutralization</article-title>. <source>Nature</source>. (<year>2016</year>) <volume>539</volume>:<fpage>314</fpage>. <pub-id pub-id-type="doi">10.1038/nature19780</pub-id><?supplied-pmid 27626374?><pub-id pub-id-type="pmid">27626374</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modis</surname><given-names>Y</given-names></name><name><surname>Ogata</surname><given-names>S</given-names></name><name><surname>Clements</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group>. <article-title>A ligand-binding pocket in the dengue virus envelope glycoprotein</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2003</year>) <volume>100</volume>:<fpage>6986</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0832193100</pub-id><?supplied-pmid 12759475?><pub-id pub-id-type="pmid">12759475</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>FA</given-names></name><name><surname>Duquerroy</surname><given-names>S</given-names></name><name><surname>Crampon</surname><given-names>E</given-names></name><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name></person-group>
<source>Crystal Structure of the Precursor Membrane Protein-Envelope Protein Heterodimer From the Yellow Fever Virus.</source>
<publisher-name>RCSB PDB</publisher-name> (<year>2017</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6EPK">https://www.rcsb.org/structure/6EPK</ext-link>.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZM</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>FL</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Crystal structure of Usutu virus envelope protein in the pre-fusion state</article-title>. <source>Virol J</source>. (<year>2018</year>) <volume>15</volume>:<fpage>183</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-018-1092-6</pub-id><?supplied-pmid 30477514?><pub-id pub-id-type="pmid">30477514</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>FA</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name><name><surname>Mandl</surname><given-names>C</given-names></name><name><surname>Kunz</surname><given-names>C</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group>. <article-title>The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution</article-title>. <source>Nature</source>. (<year>1995</year>) <volume>375</volume>:<fpage>291</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/375291a0</pub-id><?supplied-pmid 7753193?><pub-id pub-id-type="pmid">7753193</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>Retrospective identification of human cases of West Nile virus infection in Austria (2009 to 2010) by serological differentiation from Usutu and other flavivirus infections</article-title>. <source>Eurosurveillance</source>. (<year>2013</year>) <volume>18</volume>:<fpage>26</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES2013.18.43.20614</pub-id><?supplied-pmid 24176619?><pub-id pub-id-type="pmid">24176619</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>YL</given-names></name><name><surname>Hapip</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>CT</given-names></name></person-group>. <article-title>Highly sensitive TaqMan RT-PCR assay for detection and quantification of both lineages of West Nile virus RNA</article-title>. <source>J Clin Virol.</source> (<year>2006</year>) <volume>36</volume>:<fpage>177</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2006.02.008</pub-id><?supplied-pmid 16675298?><pub-id pub-id-type="pmid">16675298</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nybakken</surname><given-names>GE</given-names></name><name><surname>Oliphant</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Burke</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name></person-group>. <article-title>Structural basis of West Nile virus neutralization by a therapeutic antibody</article-title>. <source>Nature</source>. (<year>2005</year>) <volume>437</volume>:<fpage>764</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature03956</pub-id><?supplied-pmid 16193056?><pub-id pub-id-type="pmid">16193056</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Holzmann</surname><given-names>H</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs</article-title>. <source>Vaccine</source>. (<year>2009</year>) <volume>27</volume>:<fpage>7021</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.09.069</pub-id><?supplied-pmid 19789092?><pub-id pub-id-type="pmid">19789092</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradt</surname><given-names>V</given-names></name><name><surname>Malafa</surname><given-names>S</given-names></name><name><surname>von Braun</surname><given-names>A</given-names></name><name><surname>Jarmer</surname><given-names>J</given-names></name><name><surname>Tsouchnikas</surname><given-names>G</given-names></name><name><surname>Medits</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination</article-title>. <source>NPJ Vaccines.</source> (<year>2019</year>) <volume>4</volume>:<fpage>38</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-019-0133-5</pub-id><?supplied-pmid 31508246?><pub-id pub-id-type="pmid">31508246</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dokland</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>JM</given-names></name><name><surname>Khromykh</surname><given-names>AA</given-names></name><name><surname>Ee</surname><given-names>KH</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group>. <article-title>West Nile virus core protein; tetramer structure and ribbon formation</article-title>. <source>Structure</source>. (<year>2004</year>) <volume>12</volume>:<fpage>1157</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2004.04.024</pub-id><?supplied-pmid 15242592?><pub-id pub-id-type="pmid">15242592</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luca</surname><given-names>VC</given-names></name><name><surname>AbiMansour</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>CA</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name></person-group>. <article-title>Crystal structure of the Japanese encephalitis virus envelope protein</article-title>. <source>J Virol</source>. (<year>2012</year>) <volume>86</volume>:<fpage>2337</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06072-11</pub-id><?supplied-pmid 22156523?><pub-id pub-id-type="pmid">22156523</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XX</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Nian</surname><given-names>QG</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-00024-6</pub-id><?supplied-pmid 28446752?><pub-id pub-id-type="pmid">28446752</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luca</surname><given-names>VC</given-names></name><name><surname>Nelson</surname><given-names>CA</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name></person-group>. <article-title>Structure of the St. Louis Encephalitis virus postfusion envelope trimer</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<fpage>818</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01950-12</pub-id><?supplied-pmid 23115296?><pub-id pub-id-type="pmid">23115296</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivino</surname><given-names>L</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>Jovanovic</surname><given-names>V</given-names></name><name><surname>Nadua</surname><given-names>K</given-names></name><name><surname>Teo</surname><given-names>EW</given-names></name><name><surname>Pang</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Differential targeting of viral components by CD4(+) versus CD8(+) T lymphocytes in dengue virus infection</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<fpage>2693</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02675-12</pub-id><?supplied-pmid 23255803?><pub-id pub-id-type="pmid">23255803</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>CP</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Chau</surname><given-names>NV</given-names></name><name><surname>Dung</surname><given-names>NTP</given-names></name><name><surname>Chau</surname><given-names>TNB</given-names></name><name><surname>Thao</surname><given-names>LTT</given-names></name><etal/></person-group>. <article-title>Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections</article-title>. <source>J Virol</source>. (<year>2005</year>) <volume>79</volume>:<fpage>5665</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.9.5665-5675.2005</pub-id><?supplied-pmid 15827181?><pub-id pub-id-type="pmid">15827181</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>LX</given-names></name><name><surname>Jones</surname><given-names>CT</given-names></name><name><surname>Groesch</surname><given-names>TD</given-names></name><name><surname>Kuhn</surname><given-names>RJ</given-names></name><name><surname>Post</surname><given-names>CB</given-names></name></person-group>. <article-title>Solution structure of dengue virus capsid protein reveals another fold</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2004</year>) <volume>101</volume>:<fpage>3414</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0305892101</pub-id><?supplied-pmid 14993605?><pub-id pub-id-type="pmid">14993605</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sievers</surname><given-names>F</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Dineen</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Karplus</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>WZ</given-names></name><etal/></person-group>. <article-title>Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega</article-title>. <source>Mol Syst Biol</source>. (<year>2011</year>) <volume>7</volume>:<fpage>539</fpage>. <pub-id pub-id-type="doi">10.1038/msb.2011.75</pub-id><?supplied-pmid 21988835?><pub-id pub-id-type="pmid">21988835</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirohi</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>ZG</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Klose</surname><given-names>T</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Rossmann</surname><given-names>MG</given-names></name><etal/></person-group>
<article-title>The 3.8 angstrom resolution cryo-EM structure of Zika virus</article-title>. <source>Science</source>. (<year>2016</year>) <volume>352</volume>:<fpage>467</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf5316</pub-id><pub-id pub-id-type="pmid">27033547</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>PH</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Human CD4(+) T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity</article-title>. <source>J Virol</source>. (<year>2017</year>) <volume>91</volume>:<fpage>e02147</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02147-16</pub-id><?supplied-pmid 27974563?><pub-id pub-id-type="pmid">27974563</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>PH</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4(+) T-cell responses</article-title>. <source>J Infect Dis</source>. (<year>2016</year>) <volume>214</volume>:<fpage>1117</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw309</pub-id><?supplied-pmid 27443615?><pub-id pub-id-type="pmid">27443615</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Bali</surname><given-names>T</given-names></name><name><surname>Buxton</surname><given-names>G</given-names></name><name><surname>Chib</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Soni</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human T cell responses to Japanese encephalitis virus in health and disease</article-title>. <source>J Exp Med</source>. (<year>2016</year>) <volume>213</volume>:<fpage>1331</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20151517</pub-id><?supplied-pmid 27242166?><pub-id pub-id-type="pmid">27242166</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carugo</surname><given-names>O</given-names></name><name><surname>Pongor</surname><given-names>S</given-names></name></person-group>. <article-title>A normalized root-mean-square distance for comparing protein three-dimensional structures</article-title>. <source>Prot Sci</source>. (<year>2001</year>) <volume>10</volume>:<fpage>1470</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1110/ps.690101</pub-id><?supplied-pmid 11420449?><pub-id pub-id-type="pmid">11420449</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname><given-names>I</given-names></name><name><surname>Abagyan</surname><given-names>R</given-names></name></person-group>. <article-title>Methods of protein structure comparison</article-title>. <source>Methods Mol Biol.</source> (<year>2012</year>) <volume>857</volume>:<fpage>231</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-588-6_10</pub-id><?supplied-pmid 22323224?><pub-id pub-id-type="pmid">22323224</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fae</surname><given-names>I</given-names></name><name><surname>Wenda</surname><given-names>S</given-names></name><name><surname>Grill</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>GF</given-names></name></person-group>. <article-title>HLA-B<sup>*</sup>44:138Q: Evidence for a confined deletion and recombination events in an otherwise unaffected HLA-haplotype</article-title>. <source>Hla</source>. (<year>2019</year>) <volume>93</volume>:<fpage>89</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1111/tan.13439</pub-id><?supplied-pmid 30488584?><pub-id pub-id-type="pmid">30488584</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klitz</surname><given-names>W</given-names></name><name><surname>Maiers</surname><given-names>M</given-names></name><name><surname>Spellman</surname><given-names>S</given-names></name><name><surname>Baxter-Lowe</surname><given-names>LA</given-names></name><name><surname>Schmeckpeper</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>New HLA haplotype frequency reference standards: High-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans</article-title>. <source>Tissue Antigens</source>. (<year>2003</year>) <volume>62</volume>:<fpage>296</fpage>&#x02013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1034/j.1399-0039.2003.00103.x</pub-id><?supplied-pmid 12974796?><pub-id pub-id-type="pmid">12974796</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaves</surname><given-names>FA</given-names></name><name><surname>Lee</surname><given-names>AH</given-names></name><name><surname>Nayak</surname><given-names>JL</given-names></name><name><surname>Richards</surname><given-names>KA</given-names></name><name><surname>Sant</surname><given-names>AJ</given-names></name></person-group>. <article-title>The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection</article-title>. <source>J Immunol.</source> (<year>2012</year>) <volume>188</volume>:<fpage>4235</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1103640</pub-id><?supplied-pmid 22467652?><pub-id pub-id-type="pmid">22467652</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karosiene</surname><given-names>E</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Blicher</surname><given-names>T</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Buus</surname><given-names>S</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name></person-group>. <article-title>NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ</article-title>. <source>Immunogenetics</source>. (<year>2013</year>) <volume>65</volume>:<fpage>711</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00251-013-0720-y</pub-id><?supplied-pmid 23900783?><pub-id pub-id-type="pmid">23900783</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>B</given-names></name><name><surname>Giczi</surname><given-names>V</given-names></name><name><surname>Ribarics</surname><given-names>R</given-names></name><name><surname>Schreiner</surname><given-names>W</given-names></name></person-group>. <article-title>PeptX: Using Genetic Algorithms to optimize peptides for MHC binding</article-title>. <source>BMC Bioinform</source>. (<year>2011</year>) <volume>12</volume>:<fpage>241</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-12-241</pub-id><?supplied-pmid 21679477?><pub-id pub-id-type="pmid">21679477</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Dillon</surname><given-names>MBC</given-names></name><name><surname>Arlehamn</surname><given-names>CSL</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>McKinney</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>A population response analysis approach to assign class II HLA-epitope restrictions</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>194</volume>:<fpage>6164</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1403074</pub-id><?supplied-pmid 25948811?><pub-id pub-id-type="pmid">25948811</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Arlehamn</surname><given-names>CSL</given-names></name><name><surname>Schulten</surname><given-names>V</given-names></name><name><surname>Westernberg</surname><given-names>L</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Experimental validation of the RATE tool for inferring HLA restrictions of T cell epitopes</article-title>. <source>BMC Immunol</source>. (<year>2017</year>) <volume>18</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s12865-017-0204-1</pub-id><?supplied-pmid 28681704?><pub-id pub-id-type="pmid">28681704</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mettu</surname><given-names>RR</given-names></name><name><surname>Charles</surname><given-names>T</given-names></name><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>CD4+T-cell epitope prediction using antigen processing constraints</article-title>. <source>J Immunol Methods</source>. (<year>2016</year>) <volume>432</volume>:<fpage>72</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jim.2016.02.013</pub-id><?supplied-pmid 26891811?><pub-id pub-id-type="pmid">26891811</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>SJ</given-names></name></person-group>. <article-title>Helper T-cell epitope immunodominance associated with structurally stable segments of hen egg lysozyme and HIV gp120</article-title>. <source>J Theor Biol.</source> (<year>2000</year>) <volume>203</volume>:<fpage>189</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1006/jtbi.1999.1056</pub-id><?supplied-pmid 10716904?><pub-id pub-id-type="pmid">10716904</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chothia</surname><given-names>C</given-names></name><name><surname>Lesk</surname><given-names>AM</given-names></name></person-group>. <article-title>The relation between the divergence of sequence and structure in proteins</article-title>. <source>Embo J.</source> (<year>1986</year>) <volume>5</volume>:<fpage>823</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/j.1460-2075.1986.tb04288.x</pub-id><?supplied-pmid 3709526?><pub-id pub-id-type="pmid">3709526</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>EA</given-names></name><name><surname>Gates</surname><given-names>TJ</given-names></name><name><surname>LaFond</surname><given-names>RE</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Ni</surname><given-names>C</given-names></name><name><surname>Mai</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Neuroinvasive West Nile infection elicits elevated and atypically polarized t cell responses that promote a pathogenic outcome</article-title>. <source>PLoS Pathogens</source>. (<year>2016</year>) <volume>12</volume>:<fpage>e1005375</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005375</pub-id><?supplied-pmid 26795118?><pub-id pub-id-type="pmid">26795118</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assarsson</surname><given-names>E</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Oseroff</surname><given-names>C</given-names></name><name><surname>Pasquetto</surname><given-names>V</given-names></name><name><surname>Bui</surname><given-names>HH</given-names></name><name><surname>Frahm</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>178</volume>:<fpage>7890</fpage>&#x02013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7890</pub-id><?supplied-pmid 17548627?><pub-id pub-id-type="pmid">17548627</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backert</surname><given-names>L</given-names></name><name><surname>Kohlbacher</surname><given-names>O</given-names></name></person-group>. <article-title>Immunoinformatics and epitope prediction in the age of genomic medicine</article-title>. <source>Genome Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>119</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-015-0245-0</pub-id><?supplied-pmid 26589500?><pub-id pub-id-type="pmid">26589500</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oseroff</surname><given-names>C</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Kotturi</surname><given-names>MF</given-names></name><name><surname>Kolla</surname><given-names>R</given-names></name><name><surname>Alam</surname><given-names>R</given-names></name><name><surname>Broide</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>Molecular determinants of T cell epitope recognition to the common timothy grass allergen</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>185</volume>:<fpage>943</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1000405</pub-id><?supplied-pmid 20554959?><pub-id pub-id-type="pmid">20554959</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paninabordignon</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>A</given-names></name><name><surname>Termijtelen</surname><given-names>A</given-names></name><name><surname>Demotz</surname><given-names>S</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group>
<article-title>Universally immunogenic T-cell epitopes - promiscuous binding to human mhc class-ii and promiscuous recognition by T-cells</article-title>. <source>Eur J Immunol</source>. (<year>1989</year>) <volume>19</volume>:<fpage>2237</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/eji.1830191209</pub-id><pub-id pub-id-type="pmid">2481588</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Schwaiger</surname><given-names>J</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Scheinost</surname><given-names>O</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human CD4(+) T helper cell responses after tick-borne encephalitis vaccination and infection</article-title>. <source>PLoS ONE</source>. (<year>2015</year>) <volume>10</volume>:<fpage>e140545</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0140545</pub-id><?supplied-pmid 26465323?><pub-id pub-id-type="pmid">26465323</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliphant</surname><given-names>T</given-names></name><name><surname>Engle</surname><given-names>M</given-names></name><name><surname>Nybakken</surname><given-names>GE</given-names></name><name><surname>Doane</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus</article-title>. <source>Nat Med</source>. (<year>2005</year>) <volume>11</volume>:<fpage>522</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1038/nm1240</pub-id><?supplied-pmid 15852016?><pub-id pub-id-type="pmid">15852016</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>B</given-names></name><name><surname>Vogt</surname><given-names>MR</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Holdaway</surname><given-names>HA</given-names></name><name><surname>Aksyuk</surname><given-names>AA</given-names></name><name><surname>Chipman</surname><given-names>PR</given-names></name><etal/></person-group>. <article-title>Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2010</year>) <volume>107</volume>:<fpage>18950</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1011036107</pub-id><?supplied-pmid 20956322?><pub-id pub-id-type="pmid">20956322</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surman</surname><given-names>S</given-names></name><name><surname>Lockey</surname><given-names>TD</given-names></name><name><surname>Slobod</surname><given-names>KS</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Riberdy</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2001</year>) <volume>98</volume>:<fpage>4587</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.071063898</pub-id><?supplied-pmid 11287644?><pub-id pub-id-type="pmid">11287644</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>SA</given-names></name><name><surname>Stambas</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>XY</given-names></name><name><surname>Slobod</surname><given-names>KS</given-names></name><name><surname>Coleclough</surname><given-names>C</given-names></name><name><surname>Zirkel</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity</article-title>. <source>J Immunol</source>. (<year>2003</year>) <volume>171</volume>:<fpage>4140</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.171.8.4140</pub-id><?supplied-pmid 14530336?><pub-id pub-id-type="pmid">14530336</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sercarz</surname><given-names>EE</given-names></name><name><surname>Maverakis</surname><given-names>E</given-names></name></person-group>. <article-title>Mhc-guided processing: binding of large antigen fragments</article-title>. <source>Nat Rev Immunol.</source> (<year>2003</year>) <volume>3</volume>:<fpage>621</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nri1149</pub-id><?supplied-pmid 12974477?><pub-id pub-id-type="pmid">12974477</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>SL</given-names></name><name><surname>Schalich</surname><given-names>J</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Mandl</surname><given-names>CW</given-names></name><name><surname>Kunz</surname><given-names>C</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>Oligomeric rearrangement of tick-borne encephalitis-virus envelope proteins induced by an acidic Ph</article-title>. <source>J Virol</source>. (<year>1995</year>) <volume>69</volume>:<fpage>695</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.69.2.695-700.1995</pub-id><?supplied-pmid 7529335?><pub-id pub-id-type="pmid">7529335</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Ganesan</surname><given-names>APV</given-names></name><name><surname>Luckashenak</surname><given-names>N</given-names></name><name><surname>Mendonca</surname><given-names>M</given-names></name><name><surname>Eisenlohr</surname><given-names>LC</given-names></name></person-group>. <article-title>Endogenous antigen processing drives the primary CD4(+) T cell response to influenza</article-title>. <source>Nat Med.</source> (<year>2015</year>) <volume>21</volume>:<fpage>1216</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3958</pub-id><?supplied-pmid 26413780?><pub-id pub-id-type="pmid">26413780</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>K</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Herrington</surname><given-names>E</given-names></name><name><surname>Lewis</surname><given-names>JA</given-names></name><name><surname>McCormick</surname><given-names>J</given-names></name><name><surname>Beasley</surname><given-names>DWC</given-names></name><etal/></person-group>. <article-title>Persistent Infection with West Nile Virus Years after Initial Infection</article-title>. <source>J Infect Diseases</source>. (<year>2010</year>) <volume>201</volume>:<fpage>2</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1086/648731</pub-id><?supplied-pmid 19961306?><pub-id pub-id-type="pmid">19961306</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanteri</surname><given-names>MC</given-names></name><name><surname>O'Brien</surname><given-names>KM</given-names></name><name><surname>Purtha</surname><given-names>WE</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Owen</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>Tregs control the development of symptomatic West Nile virus infection in humans and mice</article-title>. <source>J Clin Invest</source>. (<year>2009</year>) <volume>119</volume>:<fpage>3266</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1172/JCI39387</pub-id><?supplied-pmid 19855131?><pub-id pub-id-type="pmid">19855131</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanteri</surname><given-names>MC</given-names></name><name><surname>Kaidarova</surname><given-names>Z</given-names></name><name><surname>Peterson</surname><given-names>T</given-names></name><name><surname>Cate</surname><given-names>S</given-names></name><name><surname>Custer</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>SQ</given-names></name><etal/></person-group>. <article-title>Association between HLA class I and class II alleles and the outcome of west nile virus infection: an exploratory study</article-title>. <source>PLoS ONE.</source> (<year>2011</year>) <volume>6</volume>:<fpage>e22948</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0022948</pub-id><?supplied-pmid 21829673?><pub-id pub-id-type="pmid">21829673</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarri</surname><given-names>CA</given-names></name><name><surname>Markantoni</surname><given-names>M</given-names></name><name><surname>Stamatis</surname><given-names>C</given-names></name><name><surname>Papa</surname><given-names>A</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name><name><surname>Pervanidou</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Genetic contribution of MHC Class II genes in susceptibility to West Nile virus infection</article-title>. <source>PLoS ONE</source>. (<year>2016</year>) <volume>11</volume>:<fpage>e165952</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0165952</pub-id><?supplied-pmid 27812212?><pub-id pub-id-type="pmid">27812212</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarri</surname><given-names>CA</given-names></name><name><surname>Papadopoulos</surname><given-names>GE</given-names></name><name><surname>Papa</surname><given-names>A</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name><name><surname>Pervanidou</surname><given-names>D</given-names></name><name><surname>Baka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Amino acid signatures in the HLA class II peptide-binding region associated with protection/susceptibility to the severe West Nile Virus disease</article-title>. <source>PLoS ONE</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e205557</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0205557</pub-id><?supplied-pmid 30379846?><pub-id pub-id-type="pmid">30379846</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>C</term><def><p>capsid</p></def></def-item><def-item><term>DEN</term><def><p>Dengue</p></def></def-item><def-item><term>E</term><def><p>envelope</p></def></def-item><def-item><term>HLA</term><def><p>human leukocyte antigen</p></def></def-item><def-item><term>JE</term><def><p>Japanese encephalitis</p></def></def-item><def-item><term>M</term><def><p>membrane</p></def></def-item><def-item><term>MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>prM</term><def><p>pre-membrane</p></def></def-item><def-item><term>TBE</term><def><p>Tick-borne encephalitis</p></def></def-item><def-item><term>WN</term><def><p>West Nile</p></def></def-item><def-item><term>WND</term><def><p>West Nile virus disease</p></def></def-item><def-item><term>YF</term><def><p>Yellow fever.</p></def></def-item></def-list></glossary></back></article>